Amit Etkin - Feb 6, 2024 Form 4 Insider Report for Alto Neuroscience, Inc. (ANRO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Erin R. McQuade, Attorney-in-Fact
Stock symbol
ANRO
Transactions as of
Feb 6, 2024
Transactions value $
$50,000
Form type
4
Date filed
2/7/2024, 04:36 PM
Previous filing
Feb 1, 2024
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANRO Common Stock Conversion of derivative security +11.8K +0.99% 1.2M Feb 6, 2024 Direct F1
transaction ANRO Common Stock Purchase $50K +3.13K +0.26% $16.00* 1.21M Feb 6, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANRO Series B Preferred Stock Conversion of derivative security $0 -25K -100% $0.00* 0 Feb 6, 2024 Common Stock 11.8K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock was convertible at any time, at the holder's election, and automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis and had no expiration date.